Emergent BioSolutions Inc... (EBS)
| Bid | 5.72 |
| Market Cap | 308.91M |
| Revenue (ttm) | 1.06B |
| Net Income (ttm) | -195.41M |
| EPS (ttm) | -3.6 |
| PE Ratio (ttm) | -1.58 |
| Forward PE | 5.34 |
| Analyst | Buy |
| Ask | 5.83 |
| Volume | 632,013 |
| Avg. Volume (20D) | 1,145,500 |
| Open | 5.75 |
| Previous Close | 5.73 |
| Day's Range | 5.55 - 5.75 |
| 52-Week Range | 1.82 - 15.10 |
| Beta | 1.80 |
About EBS
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers B...
Full Company ProfileAnalyst Forecast
According to 3 analyst ratings, the average rating for EBS stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 163.85% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call TranscriptEmergent BioSolutions Inc. (NYSE:EBS ) Q4 2024 Earnings Conference Call March 3, 2025 6:00 AM ET Company Participants Frank Vargo - Assistant Treasurer Joseph Papa - President and Chief Executive Offi...
